Over 60% of Overall Pharmaceutical Intermediates Consumption Registered by CMOs & CROs, Finds FMI Study
Global sales of pharmaceutical intermediates closed in on US$ 26 billion 2018, which is likely to see modest Y-o-Y growth in 2019, by an estimated 3.6% rate. More than 70% of the pharmaceutical intermediates consumed, were generic. A moderate demand growth outlook has been projected for branded pharmaceutical intermediates.
Pharmaceutical Intermediates Market
FMI has compiled a study on the pharmaceutical intermediates market, which offers an analy...
Prominently driven by high sales of chiral intermediates, bulk drug intermediates will continue to account for over 3/5pharmaceutical intermediates market, as they collectively contribute more than 60% to the market value. Pharma and biotech companies are also likely to develop as key end users of pharmaceutical intermediates in the near future.of overall sales, followed by chemical intermediates. The report highlights pivotal role of CROs (contract research organizations) and CMOs (contract manufacturing organizations) in shaping the
Increasing prevalence of the chronic diseases, coupled with the improved rate of early diagnosis, is heavily contributing to the towering drug demand. The report opines that prevalence rate of CVDs (cardiovascular diseases) and diabetes will particularly bolster pharmaceutical intermediates consumption. Over 1/3of the pharmaceutical intermediates market revenues is accounted by application in analgesics, followed by cardiovascular drugs and oral antidiabetic drugs, as reported by the study.
Moreover, the increasing rate of seeking treatment is also likely to boost the demand for drugs. According to the report, global pandemics, such as H1N1, Ebola, and others are also accounting for fostering drug demand – thereby pushing consumption of a wide range of APIs and pharmaceutical intermediates.
A couple of years ago, the Center for drug evaluation and research (CDER) approved more than 45 novel drugs, compared to 22 in 2016. The average novel drug approval each year, is around 31 and, and thus FMI’s analysis finds that the year 2017 witnessed a significant rise in the number of drug approvals. With the number of drug approvals on a constant rise, it is highly likely that the demand for pharmaceutical raw materials such as pharmaceutical intermediates and APIs will also witness gains in the years to come.
To cater to billowing demand in drug formulations, a number of players prominently active in the global pharmaceutical intermediates landscape are maintaining focus on expanding production capacity. Merck KGaA, for an instance, has announced production capacity expansion in Aubonne, Switzerland. The new production facility is supposed to be fully functional by the end of 2023, as reported. The production capacity will be enhanced by over 50% of the existing.
Pharmaceutical intermediates manufacturers seeking cGMP (Current Good Manufacturing Practice regulations) approval from various western regulatory bodies. Key manufacturers of pharmaceutical intermediates, particularly those based in the East and South Asian regions, are focused on their efforts in gaining FDA or EMA (European Medicine Agency) regulatory approvals for their manufacturing plants.
FMI’s research marks that the production costs associated with pharmaceutical intermediates, APIs, and final drug formulations is around 50-60% less when based in emerging Asian markets, compared to that in North America and Europe. This cost benefit according to the report will continue to attract foreign investments from pharmaceutical and biopharmaceutical companies based in overseas. On the other side, leading exporters of pharmaceutical intermediates are focusing on blending the lower production costs and high quality.
The report tracks some of the key companies operating in the Pharmaceutical Intermediates market, including Chiracon GmbH, Aceto Corporation, Midas Pharma GmbH, BASF SE, Codexis, Inc., A.R. Life Sciences Private Limited, Dishman Group, ZCL Chemicals Ltd., Pfizer, Inc., Arkema Inc and Cambrex Corporation among others.
Additional insights on the global market for pharmaceutical intermediates, write in to [email protected]
About the Healthcare Division at Future Market Insights
Future Market Insights facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business. Know more about our sector coverage here
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
- Global Digital Pathology Market
- Healthcare Regulatory Affairs Outsourcing Market
- Cold Plasma Market
- Hdl Cholesterol Kits Market
- General Anesthesia Drugs Market
- Clinical Trials Market
- Electronic Medical Records Market
- Injectable Drug Delivery Market
- Microfluidics Market
- Lab Automation Market
- Lung Cancer Surgery Market
- Veterinary Vaccines Market
- Prescription Delivery Services Market
- Vital Signs Monitoring Devices Market
- Weight Loss And Obesity Management Market